LCP5 Antibody

What is the mechanism of action for anti-CCR5 antibodies in HIV prevention?

Anti-CCR5 antibodies like Leronlimab function through competitive inhibition of HIV Env-CCR5 binding. This mechanism effectively blocks viral entry into CD4+ T cells, mimicking the natural resistance seen in individuals with the CCR5 Δ32/Δ32 mutation. When anti-CCR5 antibodies bind to the CCR5 co-receptor on CD4+ T cells, they prevent the HIV envelope glycoprotein from interacting with CCR5, thus inhibiting the viral entry process. Research has demonstrated that CD4+ T cell targets from CCR5 wild-type donors treated with Leronlimab become resistant to infection with CCR5-tropic HIV while still supporting replication of CXCR4- and dual-tropic HIV .

How is receptor occupancy (RO) measured for CCR5 antibodies in tissue samples?

Receptor occupancy for CCR5 antibodies is typically measured using flow cytometry on CD4+ T cells isolated from various tissue samples. The methodology involves:

• Collection of tissue samples (lymph nodes, endoscopic duodenum biopsies, bronchoalveolar lavages)

• Isolation of CD4+ T cells from these tissues

• Flow cytometric analysis to determine the percentage of CCR5 molecules occupied by the antibody

• Comparison across different tissues to assess penetration and binding consistency

Studies with Leronlimab have shown full CCR5 receptor occupancy on CD4+ T cells from peripheral blood, lymph nodes, and mucosal tissues throughout challenge periods, indicating effective tissue penetration and consistent binding to the target receptor .

How do CCR5 antibodies differ from small-molecule CCR5 inhibitors like Maraviroc?

While both target the same receptor, CCR5 antibodies and small-molecule inhibitors demonstrate important differences:

• Mechanism: Antibodies like Leronlimab competitively inhibit the binding between HIV Env and CCR5 through epitope-specific interactions, while small-molecule inhibitors like Maraviroc induce conformational changes in CCR5 that prevent viral binding

• Duration of action: Antibodies typically have longer half-lives (allowing weekly administration) compared to small-molecule inhibitors that require daily dosing

• Tissue penetration: Antibodies show different tissue distribution patterns compared to small molecules

• Resistance profiles: Viral escape mutations differ between these agent classes

Research has shown that small-molecule CCR5 inhibitors like Maraviroc have yielded disappointing results as PrEP agents, whereas antibody-based approaches have demonstrated promising efficacy in preclinical models .

What approaches can be used to optimize anti-CCR5 antibody concentrations for different species given variations in CCR5 expression?

Optimizing anti-CCR5 antibody concentrations requires careful consideration of species-specific CCR5 expression patterns. Methodological approaches include:

• Quantitative assessment of CCR5 expression: Flow cytometric analysis to determine both frequency of CCR5+ cells and molecules per cell across different immune cell subsets

• Comparative in vitro neutralization assays: Dose-response experiments comparing inhibitory concentrations across species

• Tissue-specific expression mapping: Analyzing CCR5 expression in target tissues (gut mucosa, lymphoid tissues) across species

Research with Leronlimab demonstrated that while CCR5+ CD4+ T cell frequencies were similar between humans and macaques, macaque cells expressed higher CCR5 molecules per cell (particularly central memory CD4+ T cells). This resulted in a requirement for 10-fold higher concentrations of Leronlimab to achieve full inhibition of SHIV infection in macaque cells compared to HIV infection in human cells .

How can antibody-dependent cellular cytotoxicity (ADCC) be distinguished from direct receptor blockade in CCR5 antibody protection studies?

Discriminating between these mechanisms requires systematic experimental approaches:

• Fc region modification: Engineering antibodies with mutations that abolish Fc receptor binding while preserving antigen binding

• Comparative protection studies: Testing native antibodies versus Fc-modified variants in vivo

• Cell depletion analysis: Monitoring CCR5+ cell counts before, during, and after antibody administration

• NK cell depletion studies: Eliminating key ADCC effector cells to assess impact on protection

In studies with Leronlimab, researchers observed dose-dependent increases in peripheral blood CCR5+ T cell frequencies during treatment (returning to baseline after antibody washout), suggesting that the antibody primarily interferes with CCR5-mediated chemotaxis rather than depleting CCR5+ cells through ADCC .

What experimental controls are necessary when evaluating anti-drug antibody (ADA) responses to CCR5 antibodies?

Rigorous evaluation of ADA responses requires:

• Serial plasma sampling: Collection at strategic timepoints (baseline, early/mid/late treatment)

• Two-step detection assay: Initial screening assay followed by confirmatory competitive binding assay

• Functional correlation: Assessing the relationship between ADA titers and:

  • Circulating free antibody levels

  • Receptor occupancy measurements

  • Pharmacodynamic effects (e.g., protection from infection)

• Species-specific considerations: Accounting for immunogenicity risks in xenogeneic systems

In macaque studies with Leronlimab, ADA responses were monitored and correlated with loss of CCR5 receptor occupancy. One animal (37032) developed ADA that resulted in loss of CCR5 RO, which correlated with subsequent SHIV infection—highlighting the importance of monitoring this phenomenon .

What experimental methods are used to evaluate the inhibitory capacity of anti-C5 antibodies?

Evaluating anti-C5 antibody function typically employs multiple complementary assays:

• Liposome lysis assay: Liposomes sensitized with antibodies against dinitrophenyl are incubated with human serum containing anti-C5 antibodies, and the degree of membrane attack complex (MAC)-induced lysis is measured

• C5a generation assay: ELISA-based quantification of C5a production during complement activation

• Pathway-specific inhibition assays: Testing inhibition across all three activation pathways (classical, alternative, and lectin pathways)

• Cross-species activity assessment: Comparative inhibition assays using sera from different species

Research on anti-C5 antibodies like eculizumab and SKY59 has demonstrated that these assays can effectively characterize inhibitory function, with both antibodies significantly inhibiting MAC-induced liposome lysis and C5a generation .

How are anti-C5 antibodies characterized for target binding properties?

Characterization of anti-C5 antibody binding properties involves:

• ELISA-based binding assays: Measuring relative binding at different pH conditions

• Surface plasmon resonance (SPR): Determining binding kinetics (association/dissociation rates) and affinity constants

• Epitope mapping: Identifying binding sites through X-ray crystallography or hydrogen-deuterium exchange mass spectrometry

• Competitive binding assays: Assessing competition with other anti-C5 antibodies or natural ligands

For pH-dependent antibodies like SKY59, researchers use binding assays at both physiological pH (7.4) and endosomal pH (5.8) to identify candidates with preferential binding at neutral pH, enabling antibody recycling technology .

What are the methodological approaches for designing recycling antibodies against C5?

Designing recycling antibodies against C5 involves multiple sophisticated steps:

• Immunization and initial screening: Generate antibodies against C5 and screen for pH-dependent binding through ELISA and Biacore analysis

• Engineering for pH dependency: Modify complementarity-determining regions (CDRs) to introduce histidines that confer pH-sensitive binding

• Structural characterization: Use X-ray crystallography to identify key interaction sites, particularly histidine clusters that mediate pH-dependent binding

• In vitro recycling assessment: Evaluate antibody recycling in cell-based assays that mimic endosomal trafficking

• Pharmacokinetic optimization: Engineer Fc regions for enhanced FcRn binding to further extend half-life

In the development of SKY59, researchers identified that a histidine cluster located on C5 is crucial for pH-dependent interaction, representing a novel mechanism distinct from other pH-dependent antibodies .

What experimental approaches can address the challenge of C5 variant resistance to therapeutic antibodies?

Overcoming C5 variant resistance requires systematic experimental approaches:

• Variant mapping: Identify and characterize C5 variants associated with reduced therapeutic response

• Alternative epitope targeting: Design antibodies targeting conserved epitopes distant from mutation sites

• Combinatorial targeting: Develop antibodies that engage multiple distinct epitopes simultaneously

• In vitro validation: Test antibody candidates against a panel of C5 variants using complement activity assays

• Structural biology insights: Use crystallography to understand the molecular basis of resistance

Research on SKY59 demonstrated its neutralizing effect on the C5 variant p.Arg885His, which is resistant to eculizumab. This finding suggests that targeting alternative epitopes can overcome variant-based resistance mechanisms .

How can cross-species reactivity be engineered into anti-C5 antibodies for preclinical model development?

Engineering cross-species reactivity involves:

• Comparative sequence analysis: Aligning C5 sequences across species to identify conserved regions

• Epitope-focused immunization: Designing immunization strategies targeting conserved regions

• Screening cascade: Progressive screening across multiple species' C5 proteins

• Mutagenesis-based optimization: Targeted modification of CDRs to accommodate species-specific differences

• In vivo validation: Confirming maintained potency in relevant animal models

Novel anti-C5 monoclonal antibodies have been developed that, unlike eculizumab, inhibit efficiently across species (human, rabbit, rat, guinea pig, and mouse). This cross-reactivity makes them powerful tools for proof-of-concept animal studies, enabling preclinical evaluation in diverse animal models including rat models of myasthenia gravis .

What methodological approaches are used to develop epitope scaffolds for eliciting structure-specific antibodies?

Developing epitope scaffolds involves several advanced techniques:

• Conformational analysis: Characterizing the target epitope's native and antibody-bound conformations using structural biology methods

• Computational transplantation: Using computational techniques to identify suitable protein scaffolds and design the epitope graft

• Affinity and specificity validation: Testing candidate scaffolds for binding to target antibodies using surface plasmon resonance

• Structural validation: Crystallographic characterization to confirm proper epitope presentation

• Immunogenicity assessment: Evaluating immune responses through heterologous prime-boost strategies

Research has shown that scaffolds with varying degrees of epitope flexibility elicit different immune responses, with correlation between graft flexibility and response levels. Crystal structures of monoclonal antibodies elicited by epitope scaffolds revealed that these antibodies can induce their targets to assume predetermined shapes .

How are multispecific antibodies designed to target different epitopes on HIV envelope and host receptors?

Design and characterization of multispecific antibodies involve:

• Format selection: Choosing appropriate multispecific formats (e.g., knobs-into-holes, CrossMAb, DVD-Ig)

• Domain arrangement optimization: Testing different arrangements of binding domains to maximize function

• Functional validation: Using ELISAs to confirm binding to each target independently

• Neutralization assessment: Evaluating potency against diverse HIV pseudovirus panels

• In vivo validation: Testing efficacy in humanized mouse models

Researchers have developed trispecific antibodies that simultaneously target the host receptor CD4, co-receptor CCR5, and distinct domains in HIV-1 envelope glycoprotein. These constructs exhibited higher potency and breadth than any previously described single broadly neutralizing antibody in HIV-1 pseudovirus neutralization assays .

What statistical approaches are recommended for analyzing antibody efficacy in protection studies?

Analysis of protection study data requires robust statistical methods:

• Survival analysis: Kaplan-Meier curves and log-rank tests to compare time to infection across treatment groups

• Correlation analyses: Relating pharmacokinetic parameters (antibody concentrations), pharmacodynamic readouts (receptor occupancy), and outcomes (protection status)

• Multivariate modeling: Identifying predictors of protection using multiple variables

• Power calculations: Determining appropriate sample sizes based on expected effect sizes

In CCR5 antibody studies, researchers analyzed protection rates across different dose groups and correlated protection with plasma drug concentrations and tissue receptor occupancy. These analyses revealed that full CCR5 receptor occupancy on tissue CD4+ T cells was associated with protection from SHIV infection .

How should researchers interpret discrepancies between in vitro neutralization and in vivo protection data?

Addressing discrepancies requires systematic interpretation approaches:

• Pharmacokinetic/pharmacodynamic analysis: Comparing antibody concentrations achieved in vivo versus those used in vitro

• Tissue distribution assessment: Evaluating antibody penetration into relevant anatomical compartments

• Immune effector engagement: Considering contributions of Fc-mediated effector functions absent in vitro

• Resistance mechanism mapping: Investigating emergent resistance pathways in vivo

• Host factors evaluation: Assessing impact of host genetics, microbiome, or immune status

Studies with anti-CCR5 antibodies have shown that while certain concentrations may achieve complete inhibition in vitro, in vivo protection may require higher doses to account for tissue-specific factors and variable receptor expression across anatomical sites .

How might data from People Also Ask boxes be leveraged to identify emerging research questions about antibody therapeutics?

Researchers can utilize PAA data through systematic approaches:

• Systematic scraping: Using tools to extract PAA questions related to antibody research terms

• Content analysis: Categorizing questions to identify knowledge gaps and emerging trends

• Temporal tracking: Monitoring changes in question patterns over time

• Cross-referencing with citation trends: Comparing public interest (PAA questions) with scientific focus (citation patterns)

• Research prioritization: Using identified gaps to inform study design and grant applications

Scraping Google SERPs for People Also Ask features can reveal what information users are searching for, which can supplement SEO and content research strategies. PAA boxes appear in approximately 30% of monitored queries, representing a valuable data source for identifying research priorities .

What methodological approaches can address the challenge of designing antibodies with predetermined specificity profiles?

Creating antibodies with customized specificity involves:

• Computational antibody design: Using structural modeling to predict antibody-antigen interactions

• Machine learning approaches: Training models on experimental data to infer design rules

• High-throughput screening platforms: Testing large libraries of variants with defined selection pressures

• Directed evolution techniques: Sequential rounds of mutation and selection to optimize specificity

• Validation across different antigens: Testing predicted specificity rules on diverse targets

Researchers have developed computational techniques to predict antibody specificity from experimental data, enabling the design of protein sequences with highly specific binding profiles. These approaches help discriminate between very similar ligands, addressing challenges in biotechnological and biomedical applications .